Please login to the form below

Not currently logged in
Email:
Password:

Horizant

This page shows the latest Horizant news and features for those working in and with pharma, biotech and healthcare.

US shortage of GSK’s restless legs syndrome treatment Horizant

US shortage of GSK’s restless legs syndrome treatment Horizant

US shortage of GSK’ s restless legs syndrome treatment Horizant. FDA blames contract manufacturer delays. ... Then in November 2012, GSK and XenoPort agreed to end their collaboration, with all rights returned to Horizant's inventors XenoPort.

Latest news

  • GSK and XenoPort end restless legs syndrome collaboration GSK and XenoPort end restless legs syndrome collaboration

    GSK and XenoPort end restless legs syndrome collaboration. Follows tough approval period for Horizant and subsequent poor sales . ... GlaxoSmithKline (GSK) has ended its collaboration with XenoPort to commercialise the restless legs syndrome drug

  • Horizant gets post-shingles pain indication in US

    Horizant gets post-shingles pain indication in US. FDA approval comes as XenoPort and partner GlaxoSmithKline remain in dispute over commercial activities to promote drug. ... XenoPort and partner GlaxoSmithKline have won approval to extend the

  • GSK sales fall for first quarter of 2011

    Recent approvals for GSK include lupus drug Benlysta (belimumab), Horizant (gabapentin enacarbil) for Restless Legs Syndrome and epilepsy treatment Trobalt (retigabine).

  • GSK Restless Legs Syndrome drug approved

    GSK Restless Legs Syndrome drug approved. GlaxoSmithKline and XenoPort have won marketing approval from the US Food and Drug Administration for Horizant, a treatment for moderate-to-severe primary Restless Legs ... Horizant's approval for the condition

  • FDA rejects GSK and Xenoport's Horizant

    The two companies submitted a New Drug Application (NDA) for Horizant extended-release tablets, to the FDA in January 2009. ... Horizant is developed from a variant of Pfizer's Nerontin (gabentin), used to control seizures in epilepsy patients.

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Deal Watch May 2016 Deal Watch May 2016

    399-616. Xenoport/ Arbor Pharmaceuticals. Corporate acquisition. Acquisition for $7.03 per share [60% premium]; includes Horizant [gabapentin] for restless legs.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • XenoPort appoints chief medical officer XenoPort appoints chief medical officer

    Dr Kim has been with the US biopharma company since July 2013, when he joined as VP of medical affair, supporting the marketing of Horizant (gabapentin enacarbil) in restless legs syndrome

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics